Study of Remimazolam for Cataract Surgery
Key facts
- Who runs it
- Fred E, Shapiro
- Where
- Boston, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 30 people, planned
- Started
- 15 Sept 2026
- Expected to end
- 1 Jun 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Arm 1 Cataract Surgery performed with remimazolam as sedative
- Arm 2 Cataract Surgery performed with standard of care sedative
- Record updated
- 15 July 2026
Who can take part
- Age
- 55 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Subject is planning to have cataract surgery in both eyes
- The surgeon estimates that each cataract surgery are estimated to take less than 30 minutes
- Subject is aged 55 to 90 years old
- Surgeries will take place on the main campus of Mass Eye and Ear at 243 Charles St., Boston for at least the first year. In the future, surgeries may also occur at Mass Eye and Ear Longwood Surgical Ambulatory Care Center
- Subject is able to understand the consent form and sign the consent
- ASA 1-3 (possible breakdown numbers of 5, 10, 10, 5)
Who cannot take part
- Subject uses concomitant home narcotic or anxiolytic
- Subject has a history of difficulty with sedation during procedures
- Subject has a history of cognitive decline
- A history of severe hepatic impairment
- The surgeon estimates that one of the planned cataract surgeries is estimated to take longer than 30 minutes
- Subject uses O2
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 55 and 90 years old?
Where in United States
- Massachusetts Eye and Ear InfirmaryBoston, United StatesContact: Vikranth R. Chinthareddy, BANot yet recruiting
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if the use of the sedative remimazolam improves the safety of patients having cataract surgery by decreasing the number of sedation-related complications during and after surgery, and shortening post-surgical cognitive recovery time.
The 2 groups in the trial
- Arm 1 Cataract Surgery performed with remimazolam as sedativeTreatment being tested
Subjects are serving as their own control. Subjects are scheduled for cataract surgery in both eyes. Sedation will be remimazolam in one eye and the standard of care in the other eye. The order of sedation will be randomly determined (50% of subjects will have remimazolam in the first eye surgery and 50% will have it in the second eye surgery.) Subjects will be blinded as to which sedation is provided at each surgery.
- Arm 2 Cataract Surgery performed with a standard of care sedativePlacebo, for comparison
Subjects are serving as their own control. Subjects are scheduled for cataract surgery in both eyes. Sedation in this arm will be the standard of care. The order of sedation will be randomly determined (50% of subjects will have remimazolam in the first eye surgery and 50% will have it in the second eye surgery.) Subjects will be blinded as to which sedation is provided at each surgery.
Treatment: Arm 2 Cataract Surgery performed with standard of care sedative
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Remimazolam for Sedation in Cataract Surgery, A Phase IV, On-label, Blinded Study
- Criteria questions
- Built from NCT07325227, who can take part
- Record updated
- 15 July 2026